Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic [Yahoo! Finance]
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: Yahoo! Finance
CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials. “Plus' CSF-01 tumor cell enumeration assay is a highly specific and sensitive diagnostic test that is promising for both establishing the diagnosis of leptomeningeal metastases (LM) and following the disease course over time,” said Dr. Priya Kumthekar, Associate Professor, Feinberg School of
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseGlobeNewswire
- Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamGlobeNewswire
- Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferenceGlobeNewswire
PSTV
Earnings
- 10/31/23 - Miss
PSTV
Sec Filings
- 3/14/24 - Form 8-K
- 3/13/24 - Form 8-K
- 3/8/24 - Form S-1/A
- PSTV's page on the SEC website